乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Public Health & Policy >

Clinical Trials

<乌鸦传媒>HypeWatch: Cannabis Bone-Healing Study Oversold

Forget the headlines you read. Here's what you should know.

<乌鸦传媒>How ASCO'S First Clinical Trial -- TAPUR -- Came To Be

ASCO's entry will evaluate off-label use of targeted agents

<乌鸦传媒>Neurologists Back FDA on Call for ALS Drug Data

Experts want Genervon to release all of its trial results for an investigational ALS drug that's already gained patient support.

<乌鸦传媒>Slippery Slope: Diet Drugs No Help for Heart

In another edition of the Slippery Slope series examining use of surrogate endpoints in drug approvals, 乌鸦传媒 and the Milwaukee Journal Sentinel find diet drugs are approved without solid evidence of benefits, but with hints of harm.

<乌鸦传媒>Brain Cancer: Did '60 Minutes' Report Raise False Hope?

Glioblastoma virotherapy touted on CBS program is promising but preliminary.

<乌鸦传媒>The NNT: An Overhyped and Confusing Statistic

Some pitfalls of summing up evidence with Numbers Needed to Treat.

<乌鸦传媒>FDA Advisers Unimpressed by Nocdurna

Another setback for nocturia indication

<乌鸦传媒>Droxidopa for OH Slammed by FDA Reviewers

SILVER SPRING, Md. -- Droxidopa (Northera) is getting a second look by an FDA advisory committee for the treatment of orthostatic hypotension stemming from neurological disorders like Parkinson's disease, but an agency review doesn't look promising for approval.

<乌鸦传媒>MoCA Beats MMSE to Assess Dementia

NEW ORLEANS -- The Montreal Cognitive Assessment (MoCA) was better than the Mini-Mental State Examination (MMSE) at teasing out subtle differences in cognitive performance among mildly impaired individuals, researchers reported here.

<乌鸦传媒>Striking a Nerve: MS Cured With an OTC Drug?

A neurology researcher is planning a clinical trial of a widely available drug that he thinks could stave off disability in multiple sclerosis patients. How much should he (or we) say publicly about it?

<乌鸦传媒>FDA Panel Vetoes New Tolvaptan Indication

SILVER SPRING, Md. -- An FDA advisory committee has declined to endorse an expanded indication for tolvaptan (Samsca) to treat autosomal dominant polycystic kidney disease.

<乌鸦传媒>Sildenafil Trial Halted in Patients with Sickle Cell Disease

LITTLE FALLS, N.J. -- The National Heart, Lung, and Blood Institute has halted a trial of sildenafil (Revatio) in sickle cell patients with pulmonary hypertension because of increased hospitalizations for sickle cell crises, or severe pain, the agency said.

<乌鸦传媒> GAO Sting Shows Independent Review Boards Are Vulnerable to Fraud

WASHINGTON -- Institutional review boards (IRBs) may not provide the clinical trial safety net they were designed to be, a federal investigation revealed.

<乌鸦传媒>Weight-Loss Trial Final Report: 52 Pounds of Fat Melted Away

WEST PALM BEACH, Fla. -- The official results are in: My ending weight was 231 pounds -- a loss of 52 pounds from my starting weight of 283 pounds in January 2008.